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sensitive pathway/mechanisms have been described. Here
we show that cold stress protein RNA binding motif 3
(RBM3) increases in neuron and astrocyte cultures main-
tained at 33 C or 36 C for 24 or 48 h, compared to 37 C
controls. Neurons cultured at 36 C also had increased glo-
bal protein synthesis (GPS). Finally, we found that mela-
tonin or ﬁbroblast growth factor 21 (FGF21) augmented
RBM3 upregulation in young neurons cooled to 36 C. Our
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cess can be pharmacologically mimicked and enhanced
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by Elsevier Ltd. on behalf of IBRO. This is an open access
article under the CC BY-NC-ND license (http://creativecom-
mons.org/licenses/by-nc-nd/4.0/).
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268INTRODUCTION
Hypothermia has long been known to have protective or
detrimental eﬀects depending on depth and duration.
For CNS injury, therapeutic hypothermia (TH) is one of
few treatments proven to reduce neurologic impairment
(Dietrich, 1992; Lyden et al., 2006; Povlishock and Wei,
2009; Wei et al., 2011). Optimal target temperature
remains a matter of debate. Each 1 C reduction in body
temperature decreases cerebral metabolism and blood
ﬂow by 6% (Rosomoﬀ and Holaday, 1954; Wong,
1983). Cooling at or below 35.5 C (but above deep
hypothermia) inversely correlates with greater neuropro-
tection (Busto et al., 1987; Minamisawa et al., 1990;
Welsh et al., 1990; Weinrauch et al., 1992). In contrast,
36 C is not thought to activate hypothermia regulated
neuroprotective mechanisms – although it does cause
thermoregulatory vasoconstriction and shivering.
Furthermore, 36 C has been used as normothermic con-
trol in a number of brain injury studies (Busto et al., 1987,
1989; Onesti et al., 1991). A recent multicenter clinical
trial on cardiac arrest found neurological outcomes were
almost identical in patients maintained to 36 C versus
those given classic TH to 33 C. Fever prevention in both
groups has been suggested to explain these surprising
outcomes. Cooling to 36 C is not a trivial intervention to
accomplish clinically (Hostler et al., 2010), and thus it is
also possible that 36 C activates as of yet unidentiﬁed
ultra-sensitive hypothermia regulated protective
mechanisms.
Cold shock proteins are up-regulated by cold stress.
They include RNA binding motif 3 (RBM3) and cold-
inducible RNA binding protein (CIRBP) (Danno et al.,
1997; Nishiyama et al., 1997). CIRBP is a novel
damage-associated molecular pattern (DAMP) that
induces inﬂammation in mice (Qiang et al., 2013).
Ischemic brain injury is reduced in CIRBP KOs (Zhou
et al., 2014). In contrast, RBM3 appears to be a potent
neuroprotective protein. RBM3 mRNA/protein is
increased in hippocampal slices by mild cooling to
33.5 C (Tong et al., 2013). Knockdown of RBM3 reduces
hypothermia mediated neuroprotection in vitro (Chip
et al., 2011). Furthermore, exposing mice to brief periods
of deep hypothermia upregulates RBM3 in the brain and
markedly reduces neurodegenerative pathologies caused
by prion or Alzheimer’s disease (Peretti et al., 2015).
Deep cooling-induced neuroprotection is blocked by
RBM3 knockdown. Non-CNS cells are also protected by
RBM3 (Ferry et al., 2011). A key function of RBM3 is to
augment global protein synthesis (GPS), which has beenons.org/licenses/by-nc-nd/4.0/).
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(Dresios et al., 2005; Smart et al., 2007; Peretti et al.,
2015). It also is a pleiotropic regulator of miRNA and
mRNAs (Pilotte et al., 2011; Liu et al., 2013).
Here we tested if RBM3 and/or CIRBP are increased
in primary cortical neuron and/or astrocyte cultures
cooled to 36 C versus conventional hypothermia to
33 C, as compared with normothermia to 37 C.
Surprisingly, 36 C upregulated RBM3 in young 6d
primary neuron cultures but failed to do so in mature 26-
d-old neurons. Also, 36 C for 48 h mildly increased
RBM3 in astrocytes. RBM3 upregulation in young
neurons cooled to 36 C was also associated with
elevated GPS. Finally, small molecule RBM3 activators
have not been reported – such drugs could theoretically
augment neurorecovery in brain-injured patients.
Fibroblast growth factor 21 (FGF21), melatonin, and
liver X receptor (LXR) agonist T0901317 increased
RBM3 levels in young neurons cooled to 36 C but were
ineﬀective in mature neurons. Our ﬁndings suggest that
even a 1 C reduction in temperature can induce a
bonaﬁde cold shock response. Sensitivity to cold shock-
induced RBM3 may be ampliﬁed in the developing brain
and capable of being pharmacologically manipulated.EXPERIMENTAL PROCEDURES
Reagents
Puromycin dihydrochloride was purchased from SIGMA
(Cat# P9620-10 mL; St. Louis, MO, USA). FGF21 was
purchased from R&D Systems (Minneapolis, MN, USA).
Melatonin, T0901317, and SRT1720 were purchased
from Tocris (Bristol, UK). AZD1080 was purchased from
Cayman Chemical (Ann Arbor, MI, USA). Primary
antibodies: Anti-RBM3 was purchased from Proteintech
Group and used at 1:1000 (Cat#14363-1-AP; Chicago,
IL, USA). Anti-CIRBP, anti-a-Tubulin, anti-
pAKT(Ser473), anti-AKT total, anti-pERK, anti-ERK
total, anti-eIF2a(Ser51), anti-eIF2a total were purchased
from Cell Signaling Technology(Danvers, MA, USA).
Anti-puromycin (12D10) was purchased from EMD
Millipore and used at 1:15,000 (Cat#MABE343; Billerica,
MA, USA). Goat anti-rabbit secondary antibodies were
purchased from Life Technologies (Grand Island, NY,
USA).Animals
Animal studies were approved by the Institutional Animal
Care and Use Committee of the University of Pittsburgh.
Euthanasia protocols follow recommendations
established by the American Medical Veterinary
Association Guideline for Euthanasia. Female timed
pregnant Sprague–Dawley rats were purchased from
Charles River (Wilmington, MA, USA) and granted ab
libitum accesses to food and water, and maintained on
a 12-h light/dark cycle prior to euthanasia to harvest
embryos.Primary cortical neuron culture
Embryos (mixed gender) were isolated from timed
pregnant (E16-17) Sprague–Dawley rats. Neuron
cultures were performed as previously described by our
group (Jackson et al., 2013). Cortices were dissected in
ice-cold Hanks balanced salt solution (HBSS; Life
Technologies, Grand Island, NY, USA) containing sodium
bicarbonate (SIGMA), penicillin–streptomycin (Life tech-
nologies), and 4-(2-hydroxyethyl)-1-piperazineethanesul
fonic acid (HEPES; Life Technologies). Brain tissues
were dissected under a Leica M651light microscope
(Buﬀalo Grove, IL, USA), and placed in a 1.5 mL tube
containing 1 mL prepared HBSS. Tissues were minced
and transferred to a 15 mL conical tube. Cells were spun
5 min/200 g/4 C. Supernatant was aspirated, cells resus-
pended in 2 mL trypsin solution, and incubated 8 min at
37 C with gentle mixing. Trypsin activity was quenched
in 10 mL Neurobasal/B27 (Life Technologies) containing
10% fetal bovine serum (FBS; Thermo Fisher Scientiﬁc,
Pittsburgh, PA, USA). Cells were transferred into a new
15 mL conical tube and spun 5 min/200 g/4 C.
Supernatant was replaced with 1.5 mL trituration media.
Cells were dissociated by 10 passages through a ﬁre-
polished glass Pasteur pipette. The cell pellet was resus-
pended in plating media warmed to 37 C (Neurobasal
Media/B27 supplement prepared + 25 lM L-Glutamic
Acid + Pen-Strep). Cell number was quantiﬁed by auto-
matic counting on a Cellometer (Nexcelom Bioscience,
Lawrence, MA, USA). Cells were seeded onto 6-well
culture plates coated with poly-D-lysine (density 1.2–
1.5  106/well). Cultures were maintained by half media
replacement every 3–4 days in vitro (DIV). The mitotic
inhibitor cytosine b-D-arabinofuranoside hydrochloride
(ARA-C; 4 lM ﬁnal concentration) was added in study 1
experiment (e.g. DIV10–11 cultures) to ensure purity of
neuronal biochemistry for initial assessment of tempera-
ture treatments. Mitotic inhibitors at low levels are non-
toxic but still potentially represent a mild stressor (though
necessary to guarantee neuron purity) (Ahlemeyer et al.,
2003). Therefore we also conﬁrmed results of tempera-
ture treatments in younger DIV6 neurons in the absence
of ARA-C (neuron enriched cultures; >90% neurons).
Astrocytes are allowed to proliferate in aged cultures,
which are not treated with ARA-C. We observe that
astrocytes are necessary for long-term survival of neuron
cultures (i.e. DIV26 mature neuron cultures).Primary astrocyte culture
Pure rat astrocyte cultures were prepared as previously
reported by our group (Jackson et al., 2013). In brief,
brains were collected from postnatal day 2 SD rat pups.
Mixed brain cells were seeded onto T75 culture ﬂasks
and maintained in DMEM/F12/10%FBS/Pen-Strep culture
media. Astrocytes were repeatedly split and propagated
in new T75 ﬂasks until pure. At propagation #5, astrocytes
were seeded onto poly-D-lysine coated 6-well plates
(7.5  104/well) and maintained for an additional 3 d.
At 60–70% conﬂuency in 6-well plates, astrocytes were
given fresh media exchange then temperature treatments
were initiated for 24 h and 48 h.
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Neurons were maintained in a 37 C (normothermic)
incubator. Before start of hypothermia, two identical
incubators of the same make/model with humidity of
95% (all in the same room) were programed to 36 C
and 33 C. Incubators were allowed a minimum of 48 h
equilibration time prior to starting hypothermic
experiments. In some experiments, as an additional
control, a thermometer was placed inside hypothermic
incubators as a secondary gauge of temperature.
Temperature as assessed by that approach was
independently conﬁrmed to never be under target
temperature and ﬂuctuate by no more than 0.5 C. On
DIV of interest, culture plates were assigned to one of
the three experimental temperatures for 24 or 48 h.
Drug treatments: Drugs were prepared in DMSO or PBS
(i.e. for FGF21). All drugs were diluted in conditioned
culture media and applied for 24 h. Controls received
equal amounts of DMSO/PBS without drugs. Primary
neurons were harvested for biochemistry at key time
points. RBM3 and CIRBP levels were measured by
Western blot. Investigators were not blinded to
temperature treatment groups.
Analysis of de novo protein synthesis
Surface sensing of translation (SUnSET) is a recently
developed non-radioactive method using puromycin
incorporation to accurately measure rate of new protein
synthesis in cells (Schmidt et al., 2009). We adapted that
protocol with a slight modiﬁcation. Brieﬂy, at the end of
temperature treatments (on DIV6), conditioned media
were collected by removing 1 mL from each well of six-
well plate, for all plates, and set aside. Conditioned media
were pooled but separated by the temperature group to
control for potential secreted proteins during 48-h treat-
ment. Pooled conditioned media (separated by tempera-
ture group) and fresh neurobasal/B27 media (stored at
4 C) were pre-warmed to 37 C. Remaining culture
media from six-well plates were then aspirated oﬀ and
replaced with either 1 mL of conditioned media (speciﬁc
for each temperature) or 1 mL fresh media; fresh
neurobasal/B27 media were applied in some neurons to
stimulate global protein synthesis. Neurons were incu-
bated for 1 h, media aspirated oﬀ, and replaced with
1.5 mL 37 C warmed PBS containing 10 ng/mL puro-
mycin. Neurons were incubated for 30 min, washed
once with ice cold PBS (without puromycin), and har-
vested for biochemistry. Investigators were not blinded
to temperature treatment groups.
Western blot
Cells were quickly washed with ice cold PBS and
harvested in RIPA buﬀer containing EDTA, protease
inhibitors, and phosphatase inhibitors (Thermo
Scientiﬁc-PIERCE). Samples were sonicated 20 s in
0.6 mL conical tubes. Homogenized material was spun
10 min/16,000 g/4 C, and supernatant was used for
downstream SDS–PAGE (whole cell extracts). Proteinconcentration was determined using the BCA assay
(Thermo Scientiﬁc-PIERCE). 15–30 lg of protein was
mixed with Laemmli loading buﬀer (BioRad, Hercules,
CA, USA). Samples were heated 95 C/5 min, and
loaded on pre-cast TGX 4–15% gradient gels (BioRad).
Gels were run at 150 V and proteins were transferred
onto polyvinylidene ﬂuoride (PVDF) membrane (GE
Healthcare Bio-Sciences, Pittsburgh, PA, USA).
Transfers were run at 100V for 1 h 15 min. During the
course of investigations GE Healthcare discontinued our
preferred PVDF membrane Hybond-P (Cat#RPN2020F).
While testing alternative PVDFs, prior to consuming
current stock, we inadvertently discovered that RBM3 is
diﬃcult to detect using some brands of membrane
(Fig. 1). This suggests PVDF selection may be an
important variable to study RBM3. All RBM3/CIRBP
Western blots in this report used (now discontinued)
Hybond-P membrane; we found it displays optimal
RBM3 binding/detection characteristics. However,
results suggest new Hybond P 0.2 membrane is also a
good alternative to detect RBM3 with lower non-speciﬁc
background. Precision Plus Kaleidoscope protein
standards (BioRad) were used for MW estimation.
Membranes were washed using 1X Tris-Buﬀered-Saline
(TBS; BioRad) and blocked in TBS-Tween-20 (TBST)
containing 7.5% blotting grade milk (TBS-T/milk) for 1 h.
Primary antibodies were prepared in TBS-T/7.5%milk
and incubated overnight in a 4 C cooler. Blots were
washed with TBS and incubated with secondary
antibodies for 2 h. Blots were given ﬁnal TBS washes,
incubated with ECL-2 HRP-detection reagent (Thermo
Fisher-PIERECE), and imaged in a dark room. Films
were scanned and compiled in Photoshop. Densitometry
analyzed by UN-SCAN-IT software (Silk Scientiﬁc,
Orem, UT, USA).Statistical analysis
Data were analyzed and graphed using GraphPad PRISM
software (GraphPad Software Inc., La Jolla, CA, USA).
Multiple comparisons were analyzed by ANOVA and
Newman–Keuls Multiple Comparison post hoc analysis.
Data were considered signiﬁcant at p< .05 using two-
tailed tests. All graphs show mean + SEM. Intrablot
group comparisons of densitometry, collected as relative
pixel intensity, were standardized for graphing by
expressing group diﬀerences as values between 0 and
1 on the y axis. In Fig. 4D, a-tubulin normalized
densitometry values were transformed to give log(Y)
values and used for statistical analysis to correct for
non-normality in distribution.RESULTS
Experimental hypothermic temperatures were tested in
pure neuron cultures as outlined (Fig. 2A). The
predicted molecular weight of RBM3 and CIRBP is
17 kDa and 18 kDa, respectively. Antibodies
detected RBM3 and CIRBP proteins in DIV11 neurons
cooled to 33 C for 48 h. Western blots show a
Fig. 1. Comparison of PVDF Membranes Used to Detect RBM3 by Western Blot. (A) Methods used to equalize factors for comparison of PVDF
membranes. Neuron homogenates (i.e. samples 1and 2) were loaded onto a 15-well 4–15% SDS gradient gel in ﬁve replicates. PVDF membranes
were precisely cut to span the width of two lanes and match gel length. Proteins were transferred to all ﬁve membranes at the same time (in the
same tank/cassette). Membranes were processed using the same volume/time incubation in blocking solution, TBS washes, primary antibody,
secondary antibody, and ECL detection reagent. Membranes were put inside a single ﬁlm holder for equivalent ﬁlm exposures in a dark room. (B)
Western blots show comparison of PVDF membranes to capture and/or detect RBM3.
T. C. Jackson et al. / Neuroscience 305 (2015) 268–278 271dominant 17 kDa RBM3 band, and a fainter 18 kDa
CIRBP band (Fig. 2B, C). We next compared 24-h
exposures to either 36 C or conventional mild
hypothermia (33 C) to induce RBM3/CIRBP in neurons
(Fig. 2D). Neuronal RBM3 protein levels were twofold
higher after 24 h 36 C, compared to 37 C
normothermic controls (Fig. 2F; n= 5/group; ANOVA,
p< 0.0001). RBM3 levels were highest in the 33 C
group at 24 h (n= 5) – although statistically signiﬁcant
this represented only a minor increase above 36 C
RBM3 levels at 24 h (Fig. 2F). By 48-h RBM3 levels in
36 C and 33 C groups were twofold higher than
37 C normothermic controls (Fig. 2E, G; n= 5/group;
ANOVA, p= 0.0169). RBM3 levels were not
signiﬁcantly diﬀerent comparing 36 C versus
conventional 33 C groups at 48 h (Fig. 2G). CIRBP was
barely detectable in primary rat neurons and did not
increase with cooling which is consistent with prior
studies by others (Fig. 2D, E).
We next tested if temperature treatments alter global
protein translation in young DIV6 neurons. Experiments
were performed as outlined (Fig. 3A). RBM3 levels
increased with 48-h cooling in both 36 C and 33 C
groups (Fig. 3B–E). In the 36 C group, RBM3 levelswere augmented more if re-warmed for 1 h in fresh
neurobasal/B27 media compared to neurons re-warmed
in conditioned media (Fig. 3D, E). In young DIV6
neurons, RBM3 levels were highest in the 33 C group -
regardless of 1-h treatment with fresh or conditioned
media. Fresh media exchange on cells is assumed to
stimulate protein translation by providing renewed
nutrients and growth factors but other factors such as
altered pH may also be involved. To validate that
assumption, de novo GPS was measured by SUnSET
in 37 C treated control neurons given conditioned or 1-
h fresh media. As expected, neurons given fresh media
had higher levels of puromycin incorporation (i.e. higher
GPS). Also, anti-puromycin antibody failed to detect
signal in DIV6 neurons that were not treated with
puromycin (Fig. 3F). Next we compared if conditioned
media versus fresh media aﬀected or unmasked,
respectively, the ability of hypothermia treatments to
alter protein translation. 36 C increased protein
synthesis in neurons given fresh media but not to the
same extent in those given conditioned media (Fig. 3G,
H). GPS was reduced in neurons given 33 C for 48 h.
Consistent with that observation, eIF2a (a master
regulator of global cap-dependent protein translation)
Fig. 2. Mild Hypothermia Increases RBM3 in DIV10–11 Neurons. (A) Timeline of experimental procedures. (B) Western blot showing speciﬁcity of
antibodies to detect RBM3 and (C) CIRBP in neurons given 33 C hypothermia for 48 h. (D) Western blot show increased RBM3 but not CIRBP in
primary cortical neurons treated 24 h or (E) 48 h with hypothermia. (F) Densitometry of protein changes for RBM3 (n= 5/group) at 24 h and (G) 48 h
(n= 5/group). Multiple comparisons were analyzed by a one-way-ANOVA and Newman–Keuls post hoc. Data were signiﬁcant at p< .05.
*Indicates post hoc signiﬁcant diﬀerence compared to 37 C normothermia. #Indicates post hoc signiﬁcant diﬀerence comparing UMH to mild
hypothermia. Graphs show mean + SEM.
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36 C or 37 C groups (i.e. increased Ser51
phosphorylation; Fig. 3I, J).
We next explored if 36 C and/or 33 C induces RBM3
in rat brain astrocytes. Astrocytes were propagated to
purity. Approximately 3d after seeding onto 6-well
plates, astrocytes were given fresh media exchange and
temperature treatments immediately initiated (Fig. 4A).
24-h exposure to hypothermia temperatures did not
appear to alter RBM3 levels compared to 37 C controls
(Fig. 4B). RBM3 was signiﬁcantly increased after 48-h
exposure to 36 C (Fig. 4C, D). However, 33 C induced
much higher levels of RBM3 compared to 36 C
(Fig. 4C, D). Phosphorylation of eIF2a in astrocytes was
unaﬀected by temperature treatments at either time
point (Fig. 4B, C).
We next screened several agents for potential RBM3
augmenting eﬀects in young neurons. DMSO (drug
dissolving vehicle) did not alter baseline RBM3 levels
(data not shown). In young DIV6 neurons, cooling to36 C for 24 h was insuﬃcient duration to induce
RBM3 (Fig. 5A) (i.e. in contrast RBM3 was mildly
increased in DIV6 neurons by 36 C for 48 h; Fig. 3B).
However, addition of FGF21 or melatonin (Mel-T)
during the shorter 24-h cooling period augmented
RBM3 levels at 36 C (Fig. 5A). The LXR agonist T090
mildly increased RBM3 levels at both 37 C and 36 C.
Neither SRT1720 (Sirtuin antagonist) nor AZD1080
(GSK-3b antagonist) increased RBM3 levels at 37 C
and 36 C. Similarly, 24-h treatment with increasing
dose of FGF21, Mel-T, and T090 had minor eﬀects on
RBM3 protein expression in DIV7 neurons cultured at
37 C (Fig. 5B). In contrast, FGF21 increased RBM3
above baseline in a bi-phasic manner when cultured at
36 C (Fig. 5C). As a positive control we also tested if
FGF21 activated AKT/ERK survival signaling at 37 C
as previously reported in neurons (Leng et al., 2015).
Paradoxically, AKT/ERK phosphorylation was decreased
24 h later potentially suggesting feedback inhibition
(Fig. 5D). Combination therapy of drugs increased
Fig. 3. Mild Hypothermia Increases RBM3 in DIV6 Neurons and Increases Protein Synthesis. (A) Timeline of experimental procedures. (B) 20-ug
protein was loaded onto gels. Western blot show increased RBM3 in primary cortical neurons treated 48 h with hypothermia and subjected to 1 h re-
warm in conditioned media (C.M.) or (C) fresh neurobasal B27 supplement (NBM/B27). (D) Densitometry of RBM3 protein changes in neurons
treated with hypothermia for 48 h (n= 3/group) and then re-warmed in C.M. or (E) Fresh NBM/B27. Multiple comparisons were analyzed by a one-
way-ANOVA and Newman–Keuls post hoc. (F) Western blot shows validation of SUnSET and eﬀect of fresh media exchange on protein translation
at 37 C. Negative control (no puromycin; NP) are ARA-C treated DIV6 neuron homogenates. Neuron homogenates incubated with puromycin for
30 min stain positive with anti-puromycin antibody indicating level of de novo protein synthesis. (G) Level of puromycin staining in neurons treated
with hypothermia and rewarmed 1 h in C.M. or (H) NBM/B27. (I) Western blot show increased phosphorylation of eIF2a in neurons treated with
hypothermia. (J) Densitometry of phosphorylated eIF2a levels, normalized to eIF2a total, in hypothermia treated neurons (n = 3/group). Data were
signiﬁcant at p< .05. *Indicates post hoc signiﬁcant diﬀerence compared to 37 C normothermia. #Indicates post hoc signiﬁcant diﬀerence
comparing UMH to mild hypothermia. Graphs show mean + SEM.
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36 C. CIRBP levels were unaﬀected by treatments
(Fig. 5E). Finally, 48 h to 36 C alone or with drugcombinations failed in induce RBM3 in mature DIV26
neurons. RBM3 was marginally increased in control neu-
rons cooled to 33 C for 48 h (Fig. 5F).
Fig. 4. Mild Hypothermia Increases RBM3 in Rat Astrocytes. (A) Timeline of experimental procedures. Western blots (20 lg/well) showing eIF2a
and RBM3 changes in astrocytes given 37 C, 36 C, or 33 C for hypothermia for (B) 24 h and (C) 48 h. (D) Densitometry of protein changes for
RBM3 (n= 3/group) at 48 h. Data were transformed to log(Y) for analysis. Multiple comparisons were analyzed by a one-way-ANOVA and
Newman–Keuls post hoc. Data were signiﬁcant at p< .05. *Indicates post hoc signiﬁcant diﬀerence compared to 37 C normothermia. #Indicates
post hoc signiﬁcant diﬀerence comparing UMH to mild hypothermia. Graphs show mean + SEM.
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Young neurons respond to cold stress in an ultra-
sensitive manner: implications for temperature
management in developmental brain injury
To the best of our knowledge only a single study has
tested if extremely mild hypothermia (a temperature
reduction of only 2 C) upregulates cold-stress proteins.
In that study, long-term maintenance of embryonic stem
cells to 35 C did not increase mRNA levels of
RBM3/CIRBP (Belinsky and Antic, 2013). Here we report
in pure primary cortical neurons and astrocytes that either
ultra-mild hypothermia (UMH) to 36 C or traditional clini-
cally used mild hypothermia levels to 33 C increase pro-
tein levels of RBM3. Notably, potentially harmful CIRBP
did not increase in neurons.
RBM3 is developmentally regulated. It is abundant in
the postnatal brain but low in adults (Pilotte et al.,
2009). We anticipated cold stress to induce RBM3 with
greater amplitude in young neurons. Consistent with that
prediction 36 C robustly increased RBM3 in young DIV6–
DIV11 neurons but not in mature DIV26 cultures. The
mechanism(s) regulating inhibition of RBM3 during CNS
development are unclear. Neurons in culture sponta-
neously ﬁre excitatory potentials beginning around
DIV7–10 followed by other progressive biochemical
changes including alterations in expression of glutamater-
gic AMPA versus NMDA receptors DIV14–21 (Zona et al.,
1994; Lin et al., 2002). Neurons adopt a more stable adult
phenotype by DIV25 (Lesuisse and Martin, 2002). Wespeculate that synaptic activity and other coordinated
developmental processes regulate epigenetic changes
suppressing protective RBM3 in the adult brain
(Martinowich et al., 2003; Fagiolini et al., 2009). Future
studies need to test that hypothesis.
Clinically conventional levels of mild TH have greater
eﬃcacy in newborns than adults with hypoxic-ischemic
brain injury (Shankaran et al., 2005; Nielsen et al.,
2013). RBM3 is more easily induced by hypothermia in
developing neurons and thus may be an underappreci-
ated component of endogenous neuroprotective
responses activated by TH in the young. The American
Academy of Pediatrics recently published 2014 recom-
mendations to enhance/extend TH in community hospi-
tals for treatment of neurological injury in neonates. It
will be important to understand if RBM3 has a role in brain
recovery in that population.Pharmacological strategies to augment RBM3
upregulation in young and mature neurons
RBM3 signaling is downregulated in the adult brain. To
the best of our knowledge only a single study
demonstrated methodology to upregulate RBM3 in the
adult brain of non-hibernating animals. In that report,
deep hypothermia to 16 C was used in combination
with 5-AMP injection to induce a hypometabolic state
which mimics conditions in hibernating animals (Peretti
et al., 2015). Induction of RBM3 by deep cooling/5-
AMP injection is ill-advised in the setting of acute brain
Fig. 5. FGF21 and Melatonin augment RBM3 induction in young neurons. (A) Western blots (n= 2) show eﬀect of 24-h treatment of DIV6 neurons
with 5 nM FGF21, 100 lM melatonin, 1 lM T090, 5 lM SRT1720, or 1 lM AZD1080. (B) Western blots show dose eﬀect of 24 h FGF21, melatonin,
or T090 at 37 C on RBM3 levels in DIV7 neurons. (C) Western blot shows dose eﬀect of 24 h FGF21 at 36 C on RBM3 levels in DIV7 neurons. (D)
Western blots show the eﬀect of FGF21 on AKT and ERK activation. (E)Western blots show eﬀect of 24-h treatment combinations (n= 3/group) to
induce RBM3 in DIV7 neurons cooled to 36 C. FGF21 was applied at 50 nM, melatonin 100 lM, and T090 at 1 lM. (F) Western blots show eﬀect of
48 h treatment combinations to induce RBM3 in DIV26 neurons cooled to 36 or 33 C. FGF21 was applied at 50 nM, melatonin 100 lM, and T090 at
1 lM (n= 3/group).
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hypothermia. Unfortunately, its obvious beneﬁts as an
easy strategy to lower core body temperature are
eclipsed by serious side eﬀects including profound
hypotension and hyperglycemia, which together aggra-
vate ischemic brain injury (Zhang et al., 2009).
Furthermore, it is well known that deep hypothermia
can exacerbate ischemic brain damage whereas mild
cooling is protective (Weinrauch et al., 1992). Given
those limitations, we attempted to identify drugs which
might safely augment RBM3 signaling under mild
hypothermic conditions. We tested several agentsincluding the hormones FGF21 and melatonin. Both
molecules cause slight body temperature reduction in
mammals (Dawson et al., 1996; Inagaki et al., 2007).
The LXR agonist T0901317 is a potential caloric restric-
tion (CR) mimetic known to upregulate RBM3 mRNA in
mouse liver as measured by microarray (Corton et al.,
2004). We also tested Sirtuin agonist SRT1720 – which
belongs to a diﬀerent class of potential CR mimetic
drugs (Smith et al., 2009). Finally, we tested the GSK-
3b inhibitor AZD1080 (Georgievska et al., 2013). GSK-
3b inhibitors activate the developmentally essential
Wnt/b-catenin pathway (Castelo-Branco et al., 2004).
276 T. C. Jackson et al. / Neuroscience 305 (2015) 268–278FGF21 and melatonin increased hypothermia-induced
RBM3 in young neurons cooled to 36 C but failed to do
so in mature neurons or young neurons incubated at
37 C. T0901317 mildly induced RBM3 in young
neurons at both temperatures but failed to do so in
mature neurons. SRT1720 and AZD1080 did not aﬀect
RBM3 levels in young neurons. Our results suggest that
FGF21 and/or melatonin merit pre-clinical evaluation
in vivo as promoters of RBM3 in the immature injured
brain. Of note, melatonin reportedly augments
hypothermia (33.5 C)-induced neuroprotection in a
piglet model of perinatal ischemic brain injury
(Robertson et al., 2013). It remains to be determined if
RBM3 could have contributed to improved outcomes in
that study. More work is needed to investigate the mech-
anism(s) underlying RBM3 induction by those compounds
in pre-clinical models of developmental brain injury.
Global protein translation is a target for treatment of
brain injury
Though not addressed by this study, we speculate RBM3
is neuroprotective in acute brain injury such as in stroke,
cardiac arrest, or traumatic brain injury. A major function
of RBM3 is to stimulate GPS (Dresios et al., 2005; Liu
et al., 2013) (Smart et al., 2007). Loss of GPS persists
in vulnerable CA1 neurons after brain ischemia, for exam-
ple, and coincides with delayed cell death (Vosler et al.,
2012). Interestingly, TH has been shown to reverse aber-
rant GPS in injured CA1 although to the best of our knowl-
edge the underlying mechanism(s) have not been
elucidated (Yamashita et al., 1991; Widmann et al.,
1993). As RBM3 is a cold shock-induced protein logic
suggests that it is in some way involved in TH-mediated
alterations in GPS. Furthermore, increasing RBM3 in
the diseased hippocampus is thought to augment GPS
which improves synaptic plasticity/sparing in vivo
(Peretti et al., 2015). Here we show for the ﬁrst time that
cooling neurons to 36 C is suﬃcient to increase RBM3
and is associated with enhanced GPS.
Unexpectedly, GPS was not increased by exposure to
33 C despite higher RBM3 levels. That observation can
be explained by overall greater inhibition of GPS in the
33 C group. Hypothermia is well known to temporally
decrease rates of GPS but at the same time upregulate
cold stress proteins prior to rewarming. In our
experiments, before harvesting neurons, all groups
received a 1-h re-warming period to 37 C in media
following 48 h of experimental temperature exposure.
The duration of time necessary for GPS to return to
normal after cooling in primary neurons has not been
reported to the best of our knowledge. It might be that
1-h rewarming was insuﬃcient to allow return of normal
translational mechanisms in the 33 C group, delaying
RBM3 from maximally augmenting GPS. In contrast
36 C, being closer to normothermia, might not alter
baseline GPS to the same extent thus facilitate the
ability of RBM3 to augment protein translation at that
temperature. This interpretation is supported by results
on eIF2a. eIF2a is a master regulation of cap-
dependent protein synthesis. Phosphorylation at Ser51
is a potent mechanism cells use to shutdown globalprotein translation (Clemens, 2001). We found eIF2a
phosphorylation was greatest in the 33 C group.
Phosphorylation of eIF2a did not increase in
astrocytes cooled to 36 C or 33 C for 48 h. Thus,
in vitro, astrocytes appear more resistant than neurons
to translational shutdown by eIF2a inhibition after mild
hypothermia. The cause of that resistance is unclear but
may relate to diﬀerences in biochemical mechanisms
regulating energy and metabolism; for instance access
to glycogen stores in astrocytes may alter protein
translation homeostasis. Alternatively, diﬀerences might
relate to relative cell culture conditions. Astrocytes were
maintained, and temperature treatments initiated, under
high serum conditions (i.e. 10% FBS). In contrast,
neurons were maintained, and temperature treatments
initiated, with serum free neurobasal/B27 supplement.
High growth factor support in astrocytes might make
them resistant to mild translational inhibition by
hypothermia. Nevertheless, RBM3 was potently induced
by 33 C and mildly increased by 36 C in astrocytes
after 48 h. Thus our work conﬁrms 36 C can increase
RBM3 in multiple CNS cell types. Future studies also
need to test if RBM3 is diﬀerentially induced by cooling
in type-1 versus type-2 astrocytes – the former being
the majority of cells in monolayer cultures in our studies.
Besides its eﬀect on GPS, RBM3 has other beneﬁcial
actions which have been noted. RBM3 knockdown blocks
mild TH-induced neuroprotection in vitro (Chip et al.,
2011). In contrast, RBM3 overexpression prevents death
in serum starved cells (Wellmann et al., 2010).Small temperature shifts may alter disease outcomes
Tiny temperature shifts are increasingly being recognized
to inﬂuence outcomes in critically ill patients. Recent trials
suggest that targeted temperature management (TTM) to
36 C is equally eﬀective on neurologic outcome and
mortality in brain-injured patients compared to
conventional TH (Nielsen et al., 2013; Moler et al.,
2015). Hyperthermia (such as by fever) exacerbates neu-
ronal death after brain ischemia (Noor et al., 2003).
Clinically, it has been shown that increases in 1 C body
temperature in the initial 72 h post hypoxic ischemic per-
iod is associated with an over threefold increase in the
odds of poor outcome in newborns (Laptook et al.,
2008). Prevention of fever is likely a key mechanism of
beneﬁt with TTM. Nevertheless it is tempting to speculate
that temperatures representing UMH might also increase
protective cold shock proteins.Ultra-mild hypothermia: semantics or biologically
relevant?
Ironically, 36 C has been used as the temperature in the
control group in many studies testing traditional levels of
TH but our data suggest it may not represent a
normothermic control –at least in young (Onesti et al.,
1991; Clark et al., 1996). Contrary to concern, classic
studies by Busto et al. in adult rodents show that mild
hypothermia to 33 C or 34 C dramatically improves his-
tological outcomes after global forebrain ischemia com-
pared to 36 C controls (Busto et al., 1987). Our ﬁndings
T. C. Jackson et al. / Neuroscience 305 (2015) 268–278 277do not prove RBM3 activation or 36 C is protective.
Rather, results suggest that it may be important to recog-
nize that extremely mild levels of hypothermia may have
biological eﬀects in some circumstances. Temperatures
slightly below normothermia may activate molecular cold
shock mechanisms in the very young – until now thought
to be only induced by traditional levels of TH. We believe
it is appropriate to consider these extremely mild temper-
ature reductions to represent UMH (i.e. 36–35.6 C).
UMH may have important distinctions from ‘‘mild
hypothermia” which technically includes 36 C but more
colloquially implies temperatures proven to induce neuro-
protection (35.5–33 C). Notwithstanding the latter deﬁni-
tion, UMH might still be neuroprotective over and above
beneﬁts gained by preventing fever after brain injury -
depending on the myriad circumstances of the model
(such as in neonates) or clinical condition. In summary,
here we show for the ﬁrst time that UMH at 36 C induces
a bonaﬁde cold-stress response in young neurons and
astrocytes in vitro.
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